Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16767293 | 0.80 | DPP4 (0.36) | DPP4L3MBTL1SMN1; SMN2 | |
| SCHEMBL2450241 | 0.77 | GBA1 (0.32) | L3MBTL1 | |
| SCHEMBL11817088 | 0.76 | L3MBTL1 (0.36) | L3MBTL1SMN1; SMN2 | |
| SCHEMBL10809053 | 0.74 | — | — | |
| SCHEMBL6839636 | 0.73 | — | — | |
| SCHEMBL432351 | 0.72 | — | — | |
| SCHEMBL815076 | 0.72 | NOS1 (0.37) | — | |
| SCHEMBL7283813 | 0.71 | DPP4 (0.40) | DPP4 | |
| SCHEMBL11653000 | 0.71 | L3MBTL1 (0.41) | L3MBTL1SMN1; SMN2 | |
| SCHEMBL11126675 | 0.71 | L3MBTL1 (0.41) | L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421887-B1 | METHOD FOR THE MANUFACTURE OF DEGARELIX | POLYPEPTIDE LABORATORIES AS (DK) | 2015-04-22 | — | — | EP | claimed |
| CN-102428097-B | Method For The Manufacture Of Degarelix | POLYPEPTIDE LABORATORIES A/S (DK) | 2014-10-29 | — | — | CN | claimed |
| US-8828938-B2 | Method for the manufacture of degarelix | POLYPEPTIDE LABORATORIES A/S (DK) | 2014-09-09 | — | — | US | claimed |
| CN-102428097-A | Method for producing degarelix | POLYPEPTIDE LABORATORIES AS (DK) | 2012-04-25 | — | — | CN | claimed |
| EP-2421887-A1 | METHOD FOR THE MANUFACTURE OF DEGARELIX | Polypeptide Laboratories A/S (DK) | 2012-02-29 | — | — | EP | claimed |
| US-20120041172-A1 | METHOD FOR THE MANUFACTURE OF DEGARELIX | POLYPEPTIDE LABORATORIES A/S (DK) | 2012-02-16 | — | — | US | claimed |
| WO-2010121835-A1 | METHOD FOR THE MANUFACTURE OF DEGARELIX | POLYPEPTIDE LABORATORIES A/S (DK) | 2010-10-28 | — | — | WO | claimed |
| US-4051140-A | VANADIA CATALYST | THE LUMMUS COMPANY (US) | 1977-09-27 | — | — | US | claimed |
| US-20150158020-A1 | SYNTHESIS OF ZEOLITES USING AN ORGANOAMMONIUM COMPOUND | UOP LLC | 2015-06-11 | — | — | US | disclosed |
| EP-2421887-B1 | METHOD FOR THE MANUFACTURE OF DEGARELIX | POLYPEPTIDE LABORATORIES AS (DK) | 2015-04-22 | — | — | EP | disclosed |
| CN-102428097-B | Method For The Manufacture Of Degarelix | POLYPEPTIDE LABORATORIES A/S (DK) | 2014-10-29 | — | — | CN | disclosed |
| US-8828938-B2 | Method for the manufacture of degarelix | POLYPEPTIDE LABORATORIES A/S (DK) | 2014-09-09 | — | — | US | disclosed |
| EP-2421887-A1 | METHOD FOR THE MANUFACTURE OF DEGARELIX | Polypeptide Laboratories A/S (DK) | 2012-02-29 | — | — | EP | disclosed |
| US-20120041172-A1 | METHOD FOR THE MANUFACTURE OF DEGARELIX | POLYPEPTIDE LABORATORIES A/S (DK) | 2012-02-16 | — | — | US | disclosed |
| WO-2010121835-A1 | METHOD FOR THE MANUFACTURE OF DEGARELIX | POLYPEPTIDE LABORATORIES A/S (DK) | 2010-10-28 | — | — | WO | disclosed |
| US-4057552-A | AMMONIATION, OXIDIZED VANADIUM OXIDE ON SUPPORT AS CATALYST | THE LUMMUS COMPANY (US) | 1977-11-08 | — | — | US | disclosed |
| US-4051140-A | VANADIA CATALYST | THE LUMMUS COMPANY (US) | 1977-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041172-A1 | METHOD FOR THE MANUFACTURE OF DEGARELIX | DNPEP, PEPD, VIP | DPP4 15/4885L3MBTL1 4433/4885SMN1; SMN2 3651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.